FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:996-1004 October 13, 1994 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Stone, P. PubMed Citation

Prostate cancer is the second leading cause of death from cancer among men; 25 percent of men with prostate cancer die of the disease¹. Moreover, many patients who do not die of prostate cancer require treatment to ameliorate symptoms such as pain, bleeding, and urinary obstruction. Thus, prostate cancer is also a major cause of suffering and of health care expenditures.

The high rate of mortality from prostate cancer may be due to late detection. In recent studies, screening for prostate cancer has combined the measurement of serum prostate-specific antigen (PSA) -- the most accurate single test for the . . . [Full Text of this Article]

Treatment of Patients with Clinically Localized Disease (Stage T1 or T2)

Watchful Waiting and Hormonal Therapy

Radical Prostatectomy

Salvage Therapy after Radical Prostatectomy

Radiation Therapy

Cost-Benefit Analysis of Potentially Curative Treatment

Treatment of Patients with Locally Advanced Disease (Stage T3)

Conservative Management

Radical Prostatectomy

Preoperative Hormonal Therapy and Radical Prostatectomy

Radiation Therapy

Salvage Treatment after the Failure of Radiation Therapy

Treatment of Patients with Lymph-Node Metastases

Treatment of Patients with Disseminated Disease

Hormonal Therapy

            Gonadotropin-Releasing Hormone Agonists

            Nonsteroidal Antiandrogens

            Other Hormonal Agents

            Maximal Androgen Ablation

Treatment of Patients with Disease Refractory to Hormonal Therapy

Secondary Hormonal Therapy

Palliative Radiation Therapy

Patients with Spinal Cord Compression

Cytotoxic Chemotherapy for Hormone-Refractory Disease

Anti-Growth Factor Treatment

Supportive Therapy

Current and Future Research

Source Information

From the Department of Surgery, Division of Urologic Surgery, Washington University School of Medicine, 4960 Children's Pl., St. Louis, MO 63110, where reprint requests should be addressed to Dr. Catalona.

References

Related Letters:

Management of Cancer of the Prostate
Stone P., Phillips C., Catalona W. J.
Extract | Full Text  
N Engl J Med 1995; 332:335-336, Feb 2, 1995. Correspondence

This article has been cited by other articles:

• Taylor, B. S., Pal, M., Yu, J., Laxman, B., Kalyana-Sundaram, S., Zhao, R., Menon, A., Wei, J. T., Nesvizhskii, A. I., Ghosh, D., Omenn, G. S., Lubman, D. M., Chinnaiyan, A. M., Sreekumar, A. (2008). Humoral Response Profiling Reveals Pathways to Prostate Cancer Progression. Mol. Cell. Proteomics 7: 600-611 [Abstract] [Full Text]  
• Greenspan, S. L. (2008). Approach to the Prostate Cancer Patient with Bone Disease. J. Clin. Endocrinol. Metab. 93: 2-7 [Abstract] [Full Text]  
• Nam, R. K., Toi, A., Klotz, L. H., Trachtenberg, J., Jewett, M. A.S., Appu, S., Loblaw, D. A., Sugar, L., Narod, S. A., Kattan, M. W. (2007). Assessing Individual Risk for Prostate Cancer. JCO 25: 3582-3588 [Abstract] [Full Text]  
• Bedolla, R., Prihoda, T. J., Kreisberg, J. I., Malik, S. N., Krishnegowda, N. K., Troyer, D. A., Ghosh, P. M. (2007). Determining Risk of Biochemical Recurrence in Prostate Cancer by Immunohistochemical Detection of PTEN Expression and Akt Activation. Clin. Cancer Res. 13: 3860-3867 [Abstract] [Full Text]  
• Greenspan, S. L., Nelson, J. B., Trump, D. L., Resnick, N. M. (2007). Effect of Once-Weekly Oral Alendronate on Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: A Randomized Trial. ANN INTERN MED 146: 416-424 [Abstract] [Full Text]  
• Lara, P. N. Jr., Stadler, W. M., Longmate, J., Quinn, D. I., Wexler, J., Van Loan, M., Twardowski, P., Gumerlock, P. H., Vogelzang, N. J., Vokes, E. E., Lenz, H. J., Doroshow, J. H., Gandara, D. R. (2006). A Randomized Phase II Trial of the Matrix Metalloproteinase Inhibitor BMS-275291 in Hormone-Refractory Prostate Cancer Patients with Bone Metastases. Clin. Cancer Res. 12: 1556-1563 [Abstract] [Full Text]  
• Bradley, S. V., Oravecz-Wilson, K. I., Bougeard, G., Mizukami, I., Li, L., Munaco, A. J., Sreekumar, A., Corradetti, M. N., Chinnaiyan, A. M., Sanda, M. G., Ross, T. S. (2005). Serum Antibodies to Huntingtin Interacting Protein-1: A New Blood Test for Prostate Cancer. Cancer Res. 65: 4126-4133 [Abstract] [Full Text]  
• Mentor-Marcel, R., Lamartiniere, C. A., Eltoum, I. A., Greenberg, N. M., Elgavish, A. (2005). Dietary Genistein Improves Survival and Reduces Expression of Osteopontin in the Prostate of Transgenic Mice with Prostatic Adenocarcinoma (TRAMP). J. Nutr. 135: 989-995 [Abstract] [Full Text]  
• Hodgson, M. C., Astapova, I., Cheng, S., Lee, L. J., Verhoeven, M. C., Choi, E., Balk, S. P., Hollenberg, A. N. (2005). The Androgen Receptor Recruits Nuclear Receptor CoRepressor (N-CoR) in the Presence of Mifepristone via Its N and C Termini Revealing a Novel Molecular Mechanism for Androgen Receptor Antagonists. J. Biol. Chem. 280: 6511-6519 [Abstract] [Full Text]  
• JOENSUU, T K, NILSSON, S, HOLMBERG, A R, MARQUEZ, M, TENHUNEN, M, SAARTO, T, JOENSUU, H (2004). Phase I Trial on sms-D70 Somatostatin Analogue in Advanced Prostate and Renal Cell Cancer. Ann. N. Y. Acad. Sci. 1028: 361-374 [Abstract] [Full Text]  
• Kreisberg, J. I., Malik, S. N., Prihoda, T. J., Bedolla, R. G., Troyer, D. A., Kreisberg, S., Ghosh, P. M. (2004). Phosphorylation of Akt (Ser473) is an Excellent Predictor of Poor Clinical Outcome in Prostate Cancer. Cancer Res. 64: 5232-5236 [Abstract] [Full Text]  
• Sreekumar, A., Laxman, B., Rhodes, D. R., Bhagavathula, S., Harwood, J., Giacherio, D., Ghosh, D., Sanda, M. G., Rubin, M. A., Chinnaiyan, A. M. (2004). Humoral Immune Response to {alpha}-Methylacyl-CoA Racemase and Prostate Cancer. JNCI J Natl Cancer Inst 96: 834-843 [Abstract] [Full Text]  
• Liu, Y., Kim, B. O., Kao, C., Jung, C., Dalton, J. T., He, J. J. (2004). Tip110, the Human Immunodeficiency Virus Type 1 (HIV-1) Tat-interacting Protein of 110 kDa as a Negative Regulator of Androgen Receptor (AR) Transcriptional Activation. J. Biol. Chem. 279: 21766-21773 [Abstract] [Full Text]  
• Hara, T., Nakamura, K., Araki, H., Kusaka, M., Yamaoka, M. (2003). Enhanced Androgen Receptor Signaling Correlates with the Androgen-refractory Growth in a Newly Established MDA PCa 2b-hr Human Prostate Cancer Cell Subline. Cancer Res. 63: 5622-5628 [Abstract] [Full Text]  
• Pizzi, H., Gladu, J., Carpio, L., Miao, D., Goltzman, D., Rabbani, S. A. (2003). Androgen Regulation of Parathyroid Hormone-Related Peptide Production in Human Prostate Cancer Cells. Endocrinology 144: 858-867 [Abstract] [Full Text]  
• Martinez, L. A., Yang, J., Vazquez, E. S., del Carmen Rodriguez-Vargas, M., Olive, M., Hsieh, J.-T., Logothetis, C. J., Navone, N. M. (2002). p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis 23: 1289-1296 [Abstract] [Full Text]  
• Masiello, D., Cheng, S., Bubley, G. J., Lu, M. L., Balk, S. P. (2002). Bicalutamide Functions as an Androgen Receptor Antagonist by Assembly of a Transcriptionally Inactive Receptor. J. Biol. Chem. 277: 26321-26326 [Abstract] [Full Text]  
• Cheng, S., Brzostek, S., Lee, S. R., Hollenberg, A. N., Balk, S. P. (2002). Inhibition of the Dihydrotestosterone-Activated Androgen Receptor by Nuclear Receptor Corepressor. Mol. Endocrinol. 16: 1492-1501 [Abstract] [Full Text]  
• Karashima, T., Sweeney, P., Slaton, J. W., Kim, S. J., Kedar, D., Izawa, J. I., Fan, Z., Pettaway, C., Hicklin, D. J., Shuin, T., Dinney, C. P. N. (2002). Inhibition of Angiogenesis by the Antiepidermal Growth Factor Receptor Antibody ImClone C225 in Androgen-independent Prostate Cancer Growing Orthotopically in Nude Mice. Clin. Cancer Res. 8: 1253-1264 [Abstract] [Full Text]  
• Zapata, P. D., Ropero, R. M., Valencia, A. M., Buscail, L., Lopez, J. I., Martin-Orozco, R. M., Prieto, J. C., Angulo, J., Susini, C., Lopez-Ruiz, P., Colas, B. (2002). Autocrine Regulation of Human Prostate Carcinoma Cell Proliferation by Somatostatin through the Modulation of the SH2 Domain Containing Protein Tyrosine Phosphatase (SHP)-1. J. Clin. Endocrinol. Metab. 87: 915-926 [Abstract] [Full Text]  
• Yuan, X., Lu, M. L., Li, T., Balk, S. P. (2001). SRY Interacts with and Negatively Regulates Androgen Receptor Transcriptional Activity. J. Biol. Chem. 276: 46647-46654 [Abstract] [Full Text]  
• Murillo, H., Huang, H., Schmidt, L. J., Smith, D. I., Tindall, D. J. (2001). Role of PI3K Signaling in Survival and Progression of LNCaP Prostate Cancer Cells to the Androgen Refractory State. Endocrinology 142: 4795-4805 [Abstract] [Full Text]  
• Muhammad Ali Tahir, S., Cheng, O., Shaulov, A., Koezuka, Y., Bubley, G. J., Wilson, S. B., Balk, S. P., Exley, M. A. (2001). Loss of IFN-{gamma} Production by Invariant NK T Cells in Advanced Cancer. J. Immunol. 167: 4046-4050 [Abstract] [Full Text]  
• Stanbrough, M., Leav, I., Kwan, P. W. L., Bubley, G. J., Balk, S. P. (2001). Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc. Natl. Acad. Sci. USA 10.1073/pnas.191235898v1 [Abstract] [Full Text]  
• Yang, J., Fizazi, K., Peleg, S., Sikes, C. R., Raymond, A. K., Jamal, N., Hu, M., Olive, M., Martinez, L. A., Wood, C. G., Logothetis, C. J., Karsenty, G., Navone, N. M. (2001). Prostate Cancer Cells Induce Osteoblast Differentiation through a Cbfa1-dependent Pathway. Cancer Res. 61: 5652-5659 [Abstract] [Full Text]  
• Stoch, S. A., Parker, R. A., Chen, L., Bubley, G., Ko, Y.-J., Vincelette, A., Greenspan, S. L. (2001). Bone Loss in Men with Prostate Cancer Treated with Gonadotropin-Releasing Hormone Agonists. J. Clin. Endocrinol. Metab. 86: 2787-2791 [Abstract] [Full Text]  
• Henshall, S. M., Quinn, D. I., Lee, C. S., Head, D. R., Golovsky, D., Brenner, P. C., Delprado, W., Stricker, P. D., Grygiel, J. J., Sutherland, R. L. (2001). Overexpression of the Cell Cycle Inhibitor p16INK4A in High-grade Prostatic Intraepithelial Neoplasia Predicts Early Relapse in Prostate Cancer Patients. Clin. Cancer Res. 7: 544-550 [Abstract] [Full Text]  
• Henshall, S. M., Quinn, D. I., Lee, C. S., Head, D. R., Golovsky, D., Brenner, P. C., Delprado, W., Stricker, P. D., Grygiel, J. J., Sutherland, R. L. (2001). Altered Expression of Androgen Receptor in the Malignant Epithelium and Adjacent Stroma Is Associated with Early Relapse in Prostate Cancer. Cancer Res. 61: 423-427 [Abstract] [Full Text]  
• Yamamoto, A., Hashimoto, Y., Kohri, K., Ogata, E., Kato, S.-a., Ikeda, K., Nakanishi, M. (2000). Cyclin E As a Coactivator of the Androgen Receptor. J. Cell Biol. 150: 873-880 [Abstract] [Full Text]  
• McDonald, S., Brive, L., Agus, D. B., Scher, H. I., Ely, K. R. (2000). Ligand Responsiveness in Human Prostate Cancer: Structural Analysis of Mutant Androgen Receptors from LNCaP and CWR22 Tumors. Cancer Res. 60: 2317-2322 [Abstract] [Full Text]  
• Navone, N. M., Rodriguez-Vargas, M. d. C., Benedict, W. F., Troncoso, P., McDonnell, T. J., Zhou, J.-H., Luthra, R., Logothetis, C. J. (2000). TabBO: A Model Reflecting Common Molecular Features of Androgen-independent Prostate Cancer. Clin. Cancer Res. 6: 1190-1197 [Abstract] [Full Text]  
• Ye, D., Mendelsohn, J., Fan, Z. (1999). Androgen and Epidermal Growth Factor Down-Regulate Cyclin-dependent Kinase Inhibitor p27Kip1 and Costimulate Proliferation of MDA PCa 2a and MDA PCa 2b Prostate Cancer Cells. Clin. Cancer Res. 5: 2171-2177 [Abstract] [Full Text]  
• Yeap, B. B., Krueger, R. G., Leedman, P. J. (1999). Differential Posttranscriptional Regulation of Androgen Receptor Gene Expression by Androgen in Prostate and Breast Cancer Cells. Endocrinology 140: 3282-3291 [Abstract] [Full Text]  
• Taplin, M.-E., Bubley, G. J., Ko, Y.-J., Small, E. J., Upton, M., Rajeshkumar, B., Balk, S. P. (1999). Selection for Androgen Receptor Mutations in Prostate Cancers Treated with Androgen Antagonist. Cancer Res. 59: 2511-2515 [Abstract] [Full Text]  
• Huang, H., Reed, C. P., Zhang, J.-S., Shridhar, V., Wang, L., Smith, D. I. (1999). Carboxypeptidase A3 (CPA3): A Novel Gene Highly Induced by Histone Deacetylase Inhibitors during Differentiation of Prostate Epithelial Cancer Cells. Cancer Res. 59: 2981-2988 [Abstract] [Full Text]  
• Yu, D.-C., Sakamoto, G. T., Henderson, D. R. (1999). Identification of the Transcriptional Regulatory Sequences of Human Kallikrein 2 and Their Use in the Construction of Calydon Virus 764, an Attenuated Replication Competent Adenovirus for Prostate Cancer Therapy. Cancer Res. 59: 1498-1504 [Abstract] [Full Text]  
• Chen, S., Song, C. S., Lavrovsky, Y., Bi*, B., Chatterjee, B., Roy, A. K. (1998). Catalytic Cleavage of the Androgen Receptor Messenger RNA and Functional Inhibition of Androgen Receptor Activity by a Hammerhead Ribozyme. Mol. Endocrinol. 12: 1558-1566 [Abstract] [Full Text]  
• Kokontis, J. M., Hay, N., Liao, S. (1998). Progression of LNCaP Prostate Tumor Cells during Androgen Deprivation: Hormone-Independent Growth, Repression of Proliferation by Androgen, and Role for p27Kip1 in Androgen-Induced Cell Cycle Arrest. Mol. Endocrinol. 12: 941-953 [Abstract] [Full Text]  
• Russell, P. J., Bennett, S., Stricker, P. (1998). Growth factor involvement in progression of prostate cancer. Clin. Chem. 44: 705-723 [Abstract] [Full Text]  
• Imperato, P. J., Nenner, R. P., Will, T. O. (1996). Trends in Radical Prostatectomy in New York State. American Journal of Medical Quality 11: 205-213 [Abstract]  
• Schuur, E. R., Henderson, G. A., Kmetec, L. A., Miller, J. D., Lamparski, H. G., Henderson, D. R. (1996). Prostate-specific Antigen Expression Is Regulated by an Upstream Enhancer. J. Biol. Chem. 271: 7043-7051 [Abstract] [Full Text]  
• Bubley, G. J., Balk, S. P. (1996). Treatment of Androgen-Independent Prostate Cancer. The Oncologist 1: 30-35 [Abstract] [Full Text]  
• Stone, P., Phillips, C., Catalona, W. J. (1995). Management of Cancer of the Prostate. NEJM 332: 335-336 [Full Text]  
• Schroder, F. H (1995). Detection of prostate cancer. BMJ 310: 140-141 [Full Text]  
• Stanbrough, M., Leav, I., Kwan, P. W. L., Bubley, G. J., Balk, S. P. (2001). Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc. Natl. Acad. Sci. USA 98: 10823-10828 [Abstract] [Full Text]